Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 29

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 29
---
 ordinary Annual Shareholders Meeting. Mr. Olivier Samuel FOR AGAINST ABSTAIN Mr. Eran Lohan FOR AGAINST ABSTAIN Ms. Liora Oren FOR AGAINST ABSTAIN 4. Advisory vote: Composition of the new Senior Management following the Merger Due to the transactions contemplated by the Merger, the Company’s senior management is intended to be newly constituted. The board proposes that the Extraordinary Shareholders Meeting approves the election of the following persons to the senior management in the sense of an advisory vote: Mr. Ronen Twito Prof. Michel Revel Mr. Kfir Malkandov Mr. Ariel Revel FOR AGAINST ABSTAIN 5. Compensation for the Members of the Board of Directors and Executive Management 5.1. Approval of the compensation for the Board of Directors The board proposes to adjust the compensation for the Board of Directors, due to the transactions contemplated by the Merger, to a new maximum aggregate amount of CHF [●] for the fixed compensation of the Board of Directors. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF [●] for the compensation of Board of Directors and the board proposes the participation in the purchase of a run-off insurance policy for the members of the Board of Directors, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. FOR AGAINST ABSTAIN 5.2. Approval of the compensation for the executive officers The board proposes to adjust the compensation for the Company’s executive officers, due to the transactions contemplated by the Merger, to a new maximum aggregate amount of CHF [●] for the fixed compensation and a new maximum aggregate amount of CHF [●] for the variable compensation of the Company’s executive officers. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF [●] for the compensation of the Company’s executive officers and the board proposes the participation in the purchase of a run-off insurance policy for the Company’s executive officers, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the financial year 2025. FOR AGAINST ABSTAIN 6. Approval of Contingent Value Rights (CVR) Agreement on an advisory vote The board proposes to